Autologous tumor cell vaccine (NCI)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAutologous tumor cell vaccine (NCI)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionInterleukin-2 stimulants
TargetsInterleukin-2
Therapy Area/IndicationsSkin MelanomaKidney NeoplasmsPlasmacytoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteChiron Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute +[4] 
Active IndicationsN/A
Inactive IndicationsSkin MelanomaKidney NeoplasmsPlasmacytoma +[6] 

Other Information

ATC CodeN/A
Related LinksN/A